{
    "clinical_study": {
        "@rank": "107759", 
        "arm_group": [
            {
                "arm_group_label": "Control", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Before the angiography 0.9 % sodium chloride 3 ml/kg/h administered for 12 hours.\nDuring the angiography and 12 hours after angiography 1 ml/kg/h 0.9 % sodium chloride administered.\n100 ml/10min 0.9 % NaCl administered intravenously just before the angiography.\n1 ml/kg/h 0.9 % sodium chloride administered intravenously during the procedure and was continued 1 hour after the angiography."
            }, 
            {
                "arm_group_label": "Dexmedetomidine", 
                "arm_group_type": "Active Comparator", 
                "description": "Before the angiography 0.9 % sodium chloride 3 ml/kg/h administered for 12 hours.\nDuring the angiography and 12 hours after angiography 1 ml/kg/h 0.9 % sodium chloride administered.\nDexmedetomidine was diluted as 1 \u03bcg/ml. 1 \u03bcg/kg/10min dexmedetomidine administered intravenously just before the angiography.\n1 \u03bcg/kg/h dexmedetomidine administered intravenously during the procedure and was continued 1 hour after the angiography."
            }
        ], 
        "brief_summary": {
            "textblock": "The aim of this study was to evaluate the effects of dexmedetomidine on renal function,\n      hormonal and hemodynamic parameters in contrast media induced diabetic patients."
        }, 
        "brief_title": "Efficacy of Dexmedetomidine in Preventing Contrast Induced Nephropathy", 
        "completion_date": {
            "#text": "July 2012", 
            "@type": "Actual"
        }, 
        "condition": "Radiographic Contrast Agent Nephropathy", 
        "condition_browse": {
            "mesh_term": "Kidney Diseases"
        }, 
        "detailed_description": {
            "textblock": "Contrast nephropathy may occur after using intravenous contrast media and may result in\n      acute renal failure. Contrast nephropathy usually reversible but in some cases it can be\n      permanent. This situation increase the time  of hospitalization and mortality  of the\n      patients. Although the only proved prevention from contrast nephropathy method is hydration,\n      infusion of dexmedetomidine may keep the renal functions."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Scheduled for percutaneous coronary angiography\n\n          -  > 18 yo\n\n          -  Diabetic patients\n\n          -  Creatinin value < 3 mg/dl\n\n        Exclusion Criteria:\n\n          -  Contrast agent hypersensitivity\n\n          -  Pregnant patients\n\n          -  Creatinin value \u22653mg/dl\n\n          -  patients have acute renal failure"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "January 13, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02137863", 
            "org_study_id": "2011/345"
        }, 
        "intervention": [
            {
                "arm_group_label": "Dexmedetomidine", 
                "description": "Intravenously 1\u03bcg/kg/10min administered just before the procedure.\n1 \u03bcg/kg/h administered during the angiography and was continued 1 hour after the angiography.", 
                "intervention_name": "Dexmedetomidine", 
                "intervention_type": "Drug", 
                "other_name": "Precedex"
            }, 
            {
                "arm_group_label": [
                    "Control", 
                    "Dexmedetomidine"
                ], 
                "description": "During 12 hours before the procedure 3 ml/kg/h 0.9 % NaCl infusion and 1 ml/kg/h during the angioplasty and 12 hours after the procedure.", 
                "intervention_name": "0.9 % NaCl", 
                "intervention_type": "Drug", 
                "other_name": "Normal Saline"
            }, 
            {
                "arm_group_label": "Control", 
                "description": "100 ml/10min infusion just before the angiography\n1 ml/kg/h infusion during the angiography and was continued 12 hours after the procedure", 
                "intervention_name": "0.9 % NaCl", 
                "intervention_type": "Drug", 
                "other_name": "Normal Saline"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Dexmedetomidine"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Contrast induced nephropathy", 
            "Diabetes Mellitus", 
            "Dexmedetomidine"
        ], 
        "lastchanged_date": "May 13, 2014", 
        "number_of_arms": "2", 
        "official_title": "Phase 4 Study of Dexmedetomidine Effects on Preventing Contrast Induced Nephropathy", 
        "overall_official": {
            "affiliation": "Erciyes University", 
            "last_name": "Aynur Ak\u0131n, Prof", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Turkey: Ethics Committee", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "June 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Changes in glomerular renal function after percutaneous coronary angiography as measured by neutrophil gelatinase-associated lipocalin, cystatin c, blood urea nitrogen, creatinin", 
            "safety_issue": "No", 
            "time_frame": "1 day (from start of angioplasty till discharge from the hospital)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02137863"
        }, 
        "responsible_party": {
            "investigator_affiliation": "TC Erciyes University", 
            "investigator_full_name": "Aynur Ak\u0131n", 
            "investigator_title": "Prof Dr", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "blood pressure", 
                "safety_issue": "No", 
                "time_frame": "1 day (from start of angiography till discharge from the hospital)"
            }, 
            {
                "measure": "Heart rate", 
                "safety_issue": "No", 
                "time_frame": "1 day (from start of angiography till discharge from the hospital)"
            }, 
            {
                "measure": "Blood electrolyte levels ( sodium, potassium, chloride)", 
                "safety_issue": "No", 
                "time_frame": "before the angiography and just before the discharge from hospital"
            }, 
            {
                "measure": "complete blood count", 
                "safety_issue": "No", 
                "time_frame": "before the angiography and just before the discharge from hospital"
            }
        ], 
        "source": "TC Erciyes University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "TC Erciyes University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2011", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}